These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Schmidt F; Weisblum Y; Muecksch F; Hoffmann HH; Michailidis E; Lorenzi JCC; Mendoza P; Rutkowska M; Bednarski E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Caskey M; Robbiani DF; Nussenzweig MC; Rice CM; Hatziioannou T; Bieniasz PD bioRxiv; 2020 Jun; ():. PubMed ID: 32577658 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Case JB; Rothlauf PW; Chen RE; Liu Z; Zhao H; Kim AS; Bloyet LM; Zeng Q; Tahan S; Droit L; Ilagan MXG; Tartell MA; Amarasinghe G; Henderson JP; Miersch S; Ustav M; Sidhu S; Virgin HW; Wang D; Ding S; Corti D; Theel ES; Fremont DH; Diamond MS; Whelan SPJ SSRN; 2020 May; ():3606354. PubMed ID: 32714117 [TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Case JB; Rothlauf PW; Chen RE; Liu Z; Zhao H; Kim AS; Bloyet LM; Zeng Q; Tahan S; Droit L; Ilagan MXG; Tartell MA; Amarasinghe G; Henderson JP; Miersch S; Ustav M; Sidhu S; Virgin HW; Wang D; Ding S; Corti D; Theel ES; Fremont DH; Diamond MS; Whelan SPJ bioRxiv; 2020 May; ():. PubMed ID: 32511401 [TBL] [Abstract][Full Text] [Related]
15. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891 [TBL] [Abstract][Full Text] [Related]
16. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511 [TBL] [Abstract][Full Text] [Related]
17. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
18. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. Lichtenegger S; Saiger S; Hardt M; Kulnik S; Wagner GE; Kleinhappl B; Assig K; Zauner A; Ober M; Kimpel J; von Laer D; Zatloukal K; Steinmetz I J Clin Microbiol; 2022 Jul; 60(7):e0037622. PubMed ID: 35642515 [TBL] [Abstract][Full Text] [Related]
19. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729 [TBL] [Abstract][Full Text] [Related]
20. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2. Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]